# The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis

> **NCT06773221** · NA · NOT_YET_RECRUITING · sponsor: **Beijing Friendship Hospital** · enrollment: 195 (estimated)

## Conditions studied

- Metabolic Dysfunction Associated Fatty Liver Disease
- Compensated Liver Cirrhosis

## Interventions

- **DRUG:** Chiglitazar 64mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06773221
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-05
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 195 (ESTIMATED)
- **Last updated:** 2025-01-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06773221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06773221, "The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06773221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*